Novavax, Inc. (NASDAQ: NVAX) has received conditional marketing authorisation from the Swissmedic for Nuvaxovid. This compound is a vaccine against COVID-19 in people aged 18 and older.
Moreover, it is the only vaccine derived from protein that Switzerland has approved.
According to the CEO and President of Novavax, Stanley C. Erck, the company is happy to have received authorisation from Switzerland. He adds that people should decide on the vaccines they want to use. Erck adds that the vaccine is safe and effective while still offering a different solution to fighting the virus.
Swissmedic examined data from clinical studies
The Swissmedic used the available data on clinical trials and manufacturing to decide. This data included two Phase III clinical studies. The first steal was PREVENT-19, where researchers gathered 30,000 volunteers 18 and above from Mexico, the U.S.
The second trial had 15,000 adults from the U.K Novavax managed to demonstrate the tolerability, efficacy and safety of the vaccine in the trials. The adverse effect was limited and not significantly more than those in the placebo groups.
Patients’ side effects during the trials were malaise, fatigue, pain in the injection site, arthralgia, myalgia, vomiting, nausea, and headache. While the company hasn’t found any complications with the vaccine, it has stated that it will track its safety and investigate its efficacy on different variants as it uses it on different populations.
The company strikes a deal with the government
Meanwhile, Novavax has a deal with the Switzerland government that it would supply about 6 million vaccine doses to the country. The company is still awaiting approval from the U.S Food and Drug Administration on its name Nuvaxovid.
The company has warned people allergic to the active component of its vaccine not to use it. Different COVID-19 vaccines have elicited anaphylaxis in patients. For this reason, administrators must observe their patients for any reactions and offer immediate treatment. Novavax recommends that physicians watch their patients for about 15 minutes after administering the vaccine.
The company has also warned that people with acute infection or febrile illness shouldn’t take the vaccine until they recover. However, this doesn’t apply to those with mild illnesses.
